Flexible docking of an acetoxyethoxymethyl derivative of thiosemicarbazone into three different species of dihydrofolate reductase

Archives of Pharmacal Research

Volumn 25, Issue 6, 2002, Pages 807-816

  Choi, In Hee ^a   Kim, Choonmi ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Binding modes; DHFR; Flexible docking; QXP program; Thiosemicarbazone

Indexed keywords

DIHYDROFOLATE REDUCTASE; THIOSEMICARBAZONE DERIVATIVE;

ARTICLE; BINDING SITE; CANDIDA ALBICANS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; CRYSTALLIZATION; ESCHERICHIA COLI; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY; PLIABILITY; SPECIES DIFFERENCE; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CANDIDA ALBICANS; COMPUTER SIMULATION; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLIABILITY; SPECIES SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE; THIOSEMICARBAZONES;

EID: 0038003893     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02976996     Document Type: Article

References (27)

1. Bohacek, R. S., Dalgarno, D. C., Hatada, M., Jacobsen, V. A., Lynch, B. A., Macek, K. J., Merry, T., Metcalf III, C. A., Narula, S. S., Sawyer, T. K., Shakespeare, W. C., Violette, S. M., and Weigele, M., X-ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor. J. Med. Chem., 44, 660-663 (2001).
2. Bolin, J. T., Filman, D. J., Matthews, D. A., Hamlin, R.C., and Kraut, J., Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 resolution. J. Biol. Chem., 257(22), 13650-13662 (1982).
3. Bruice, P. Y., Organic Chemistry (fourth eds). Prentice Hall, New Jersey, (1995).
4. + ternary complex: Substrate binding and a model for the transition state. Biochemistry, 29, 3263-3277 (1990).
5. Cody, V., Luft, J. R., Ciszak, E., Kalman, T. I., and Freisham, J. H., Crystal structure determination at 2.3 of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate - tetrazole. Anticancer Drug Design, 7, 483-491 (1992).
6. Cody, V., Wojtczak, A., Kalman, T. I., Freisham, J. H., and Blakley, R. L., Conformational analysis of human dihydrofolate reductase inhibitor complexes: Crystal structure determination of wild type and F31 mutant binary and ternary inhibitor complexes. Ayling, J. E., Nair, M. G. and Baugh, C. M. (Eds.), In Chemistry and Biology of Pteridines and Folates. Plenum Press, New York, pp. 48-486, (1993).
7. Cody, V., Galitsky, N., Luft, J. R., Pangborn, W., Gangjee, A., Devraj, R., Queener, S. F., and Blakley, R. L., Comparison of ternary complexes of Pneumocystis carinii and wild type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate. Acta Crystallographica, D53, 638 (1997).
8. Cody, V., Galitsky, N., Luft, J. R., Pangborn, W., Blakley, R. L., and Gangjee, A., Comparison of ternary crystal complexes of F31 variants of human dihydrofolate reductase with NADPH and a classical antitumor furopyrimidine. Anticancer Drug Des., 13, 307-315 (1998).
9. Cocco, L., Roth, B., Temple, C. Jr., Montgomery, J. A., London, R. E., and Blakley, R. L., Protonated state of methotrexate, trimethoprim, and pyrimethamine bound to dihydrofolate reductase. Arch. Biochem. Biophys., 226, 567-577 (1983).
10. Fierke, C. A., Johnson, K. A., and Benkovic, S. J., Construction and evaluation of the kinetics scheme associated with dihydrofolate reductase from Escherichia coli. Biochemistry, 26, 4085-4092 (1987).
11. 3-(2-acetoxyethoxymethyl) thioureas. J. Pharm. Sci., 75, 1180-1184 (1986).
12. Foye, W. O., Dabade, S. V., Kelly, C. J., Lebrun, E., and van Rapenbusch, R., Synthesis and dihydrofolate reductase inhibitory activity of N4-2-L-glutaryl-N1-heteroaryl thiosemicarbazones. Med. Chem. Res., 8, 542-553 (1998).
13. Gokhale, V. M., and Kulkarni, V. M., Selectivity analysis of 5-(arylthio)-2,4-diaminoquinazolines as inhibitors of Candida albicans dihydrofolate reductase by molecular dynamics simulations. J. Comput. Aided Mol., Des. 14, 495-500 (2000).
14. Graffner-Nordberg, M., Marelius, J., Ohlsson, S., Persson, A., Swedberg, G., Anderson, P., Andersson, S. E., Aqvist, J., and Hallberg, A., Computational predictions of binding affinities to dihydrofolate reductase: Synthesis and biological evaluation of methotrexate analogues. J. Med. Chem., 43, 3852-3861 (2000).
15. Jacques, S. L., Ejim, L. J., and Wright, G. D., Homoserine dehydrogenase from Saccharomyces cerevisiae: Kinetic mechanism and stereochemistry of hydride transfer. Biochim. Biophys. Acta, 1544, 42-54 (2001).
16. 4-(2-acetoxyethoxymethyl)-2- acetylpyridine thiosemicarbazone. Biochim. Biophys. Acta., 1034, 81-85 (1990).
17. McMartin, C., and Bohacek, R. S., QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des., 11, 333-344 (1997).
18. Meiering, E. M., and Wagner, G., Detection of long-lived bound water molecules in complexes of human dihydrofolate reductase with methotrexate and NADPH. J. Mol. Biol., 247, 294-308 (1995a).
19. Meiering, E. M., Li, H., Delcamp, T. J., Freisheim, J. H., and Wagner, G., Contributions of tryptophan 24 and glutamate 30 to binding long-lived water molecules in the ternary complex of human dihydrofolate reductase with methotrexate and NADPH studied by site-directed mutagenesis and nuclear magnetic resonance spectroscopy. J. Mol. Biol., 247, 309-325 (1995b).
20. Metcalf III, C. A., Eyermann, C. J., Bohacek, R. S., Haraldson, C. A., Varkhedkar, V. M., Lynch, B. A., Bartlett, C., Violette, S. M., and Sawyer, T. K., Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the src SH2 (Src SH2) domain. J. Comb. Chem., 2, 305-313 (2000).
21. Sawaya, M., and Kraut, J., Loop and subdomain movements in the mechanism of escherichia coli dihydrofolate reductase: Crystallographic evidence. Biochemistry, 36, 586-603 (1997).
22. Schweitzer, B. I., Dicker, A. P., and Bertino, J. R., Dihydrofolate reductase as a therapeutic target. FASEB J., 4, 2441-2452 (1990).
23. Shakespeare, W., Yang, M., Bohacek, R., Cerasoli, F., Stebbins, K., Sundaramoorthi, R., Azimioara, M., Vu, C., Pradeepan, S., Metcalf III, C., Haraldson, C., Merry, T., Dalgarno, D., Narula, S., Hatada, M., Lu, X., van Schravendijk, M. R., Adams, S., Violette, S., Smith, J., Guan, W., Bartlett, C., Herson, J., Luliucci, J., Weigele, M., and Sawyer, T., Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci., 97, 9373-9378 (2000).
24. Stilz, H. U., Guba, W., Jablonka, B., Just, M., Klingler, O., Konig, W., Wehner, V., and Zoller, G., Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. J. Med. Chem., 44, 1158-1176 (2001).
25. Vu, C. B., Corpuz, E. G., Merry, T. J., Pradeepan, S. G., Bartlett, C., Bohacek, R. S., Botfield, M. C., Eyermann, C. J., Lynch, B. A., MacNeil, I. A., Ram, M. K., van Schravendijk, M. R., Violette, S., and Sawyer, T. K., Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem., 42, 4088-4098 (1999).
26. Weiner, S. J., Kollman, P. A., Case, D. A., Singh, U. C., Ghio, C., Algona, C., Profeta, S., and Weiner, P., A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc., 106, 765-784 (1984).
27. Whitlow, M., Howard, A. J., Stewart, D., Hardman, K. D., Kuyper, L. F., Baccanari, D. P., Fling, M. E., and Tansik, R. L., X-ray crystallographic studies of Candida albicans dihydrofolate reductase: High resolution structures of the holoenzyme and an inhibited ternary complex. J. Biol. Chem., 48, 30289-30298 (1997).